ResearcherEast China Normal UniversityActive in the last 2 years
Peng He
Matched on ORCID iD 0000-0002-2129-2351; OpenAlex author ID A5084109278. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2022: 2 papers · 2023: none · 2024: 1 paper
Papers 3
- Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. Co-author DOI 10.1021/acscentsci.3c01440↗
- Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment. Co-author DOI 10.1021/acs.jmedchem.2c01554↗
- Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic cancer. Co-author DOI 10.4155/fmc-2022-0168↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yihua Chen · 3 shared papers, 2022–2024 · strength 0.48
- Paper Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. DOI 10.1021/acscentsci.3c01440↗
- Paper Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic ca… DOI 10.4155/fmc-2022-0168↗
- Paper Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatme… DOI 10.1021/acs.jmedchem.2c01554↗
- Zhengfang Yi · 3 shared papers, 2022–2024 · strength 0.48
- Paper Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. DOI 10.1021/acscentsci.3c01440↗
- Paper Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic ca… DOI 10.4155/fmc-2022-0168↗
- Paper Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatme… DOI 10.1021/acs.jmedchem.2c01554↗
- Mingyao Liu · 2 shared papers, 2022–2024 · strength 0.32
- Zhenliang Sun · 1 shared paper, 2024 · strength 0.18
- Chen Huang · 1 shared paper, 2024 · strength 0.18
- Yunqi Li · 1 shared paper, 2022 · strength 0.16
- Haijun Gu · 1 shared paper, 2022 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.